Brief: Gilead And Arcus Announce Anti-Tigit Domvanalimab Plus Zimberelimab And Chemotherapy Exceeded One Year Of Median Progression-Free Survival As A First-Line Treatment For Upper Gi Cancers
01/06/2024 13:34
Gilead Sciences Inc GILD.O :
* GILEAD AND ARCUS ANNOUNCE ANTI-TIGIT DOMVANALIMAB PLUS
ZIMBERELIMAB AND CHEMOTHERAPY EXCEEDED ONE YEAR OF MEDIAN
PROGRESSION-FREE SURVIVAL AS A FIRST-LINE TREATMENT FOR UPPER GI
CANCERS
Source text for Eikon: ID:nBw9dDD8Za
Further company coverage: GILD.O
Recent news on Arcus Biosciences
See all newsU.S. STOCKS ON THE MOVE-Quest Diagnostics, Tractor Supply, Dutch Bros
U.S. STOCKS ON THE MOVE-CME, Lockheed Martin, Valero Energy
Arcus Biosciences tumbles on $250 mln share sale
Brief: Arcus Biosciences Announces Pricing Of $250 Million Public Offering Of Common Stock
Arcus Biosciences drops after starting stock offering